AI Science Tracker
EN

Southwest Medical University

2 discoveries from 2023 to 2026

Discoveries

Bioinformatics analyses associated ANXA1 with head-and-neck cancer progression and chemotherapy resistance

Source check: Source checked. Not independent scientific confirmation.

Finding: Machine-learning analysis of tumor-expression datasets identified ANXA1-related prognostic and chemotherapy-resistance signals in head-and-neck squamous-cell carcinoma. The paper also reports cell-based experiments; computational associations and candidate-compound analyses do not establish therapeutic efficacy.

Technology: LASSO-Cox modeling of tumor datasets with AI-based virtual-cell and molecular-docking analyses.

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
LASSO-Cox modeling of tumor datasets with AI-based virtual-cell and molecular-docking analyses.
Test and result
Analyses used TCGA/GEO datasets with validation in GSE65858; cell experiments examined ANXA1-related effects. A candidate compound was computationally proposed.
Limitation / still unknown
Retrospective bioinformatics plus in-vitro experiments; no clinical treatment efficacy or prospective patient validation established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12979454/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Three-gene neural model distinguishes tumor from adjacent liver tissue arrays

Source check: Source checked. Not independent scientific confirmation.

Finding: A learned three-gene model distinguished known HBV-associated liver-tumor tissue from adjacent tissue in public expression datasets. The source reports validation AUC .849 across 140 arrays; the original dataset includes multiple samples from 11 patients. This is tissue classification, with no evidence of early screening or future cancer conversion.

Technology: Random forest, SVM-RFE, LASSO and three-gene artificial neural network

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Learned feature-selection algorithms and an ANN discriminate tissue labels; conventional enrichment and inferred immune scores are not separately counted as new experimental biology.
Test and result
Intersecting RF, SVM-RFE and LASSO selections produced HHIP, CXCL14 and CDHR2. The source used GSE121248 with 70 tumor/37 adjacent arrays for development and GSE55092 with 49 tumor/91 adjacent arrays for reported validation AUC .849(95% CI .773–.916), compared with training AUC .948. Original GEO metadata describes up to 17 whole-liver tissue samples per liver from 11 HCC patients, with selected laser-capture samples also included.
Limitation / still unknown
Array counts are not independent patient counts. Adjacent tissues come from livers already affected by HCC, not a prospective cohort of people with uncomplicated hepatitis B. Multiple regions and sample modalities can affect discrimination and uncertainty. GeneScore median thresholds were computed on each dataset, so the validation transformation is not a demonstrated frozen deployment rule. No blood test, prospective early detection, future HBV-to-cancer conversion, causal immune mechanism or clinical benefit was validated. The source association/subtype analyses reuse these datasets.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10638043/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 21 Nov 2026. Review scope: Original data definition, learned feature screening, ANN Methods and reported validation Results actually read; original GEO indexed study-design metadata independently checked..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.